

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Joost Louwagie	Confirmation: 2966
Serial No.: 18/179,945	Group No.: 1634
Filed: 03/07/2023	Examiner: Ethan C. Whisenant
Entitled: FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD	

**AMENDMENT AND RESPONSE TO NON-FINAL
OFFICE ACTION MAILED 07/06/2023**

EFS WEB FILED
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This paper is responsive to the Office Action mailed 07/06/2023, with response due by 10/06/2023. Applicant respectfully requests reconsideration in view of the remarks hereinbelow.

The Commissioner is authorized by this paper to charge any fees during the entire pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 that may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-4302, referencing Attorney Docket No.: **EXCTD-35239.307**. This paragraph is a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Amendment to the Claims begins on Page 2;

Remarks begin on Page 6.

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior listings and versions of claims in the application:

1. (original) A method of processing a freshly-collected fecal sample without freezing, the method comprising:
 - a) collecting a fecal sample from a human subject, wherein the fecal sample is collected at home by the human subject;
 - b) in a sealable vessel, combining a first portion of the fecal sample with a stabilizing buffer, and sealing the sealable vessel; and
 - c) in a sealable container, combining a second portion of the fecal sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample, and sealing the sealable container.
2. (original) The method of claim 1, further comprising delivering the sealable vessel containing the first portion of the fecal sample and the stabilizing buffer and the sealable container containing the second portion of the fecal sample and the solution to a medical diagnostics laboratory.
3. (canceled)
4. (original) A method of processing a fecal sample, the method comprising:
 - a) obtaining a pair of portions of a fecal sample collected from a human subject, the pair of portions comprising:
 - i) a sealed sealable vessel containing a first portion of a fecal sample and a stabilizing buffer; and
 - ii) a sealed sealable container containing a second portion of a fecal sample and a solution that prevents denaturation or degradation of blood proteins found in a fecal sample,

wherein the pair of portions are obtained by the method of claim 1;

- b) extracting nucleic acid from the first portion of the fecal sample;
 - c) testing nucleic acid extracted from the first portion of the fecal sample for an amount of a human nucleic acid; and
 - d) testing the second portion of the fecal sample for an amount of a blood protein present in the second portion of the fecal sample.
5. (original) The method of claim 4, wherein testing the nucleic acid comprises determining expression from a human gene.
6. (original) The method of claim 5, wherein determining expression from the human gene comprises testing the nucleic acid for presence of human DNA having an epigenetic modification.
7. (original) The method of claim 6, wherein testing the nucleic acid for the presence of human DNA having an epigenetic modification comprises measuring an amount of a methylated human DNA.
8. (original) The method of claim 6, wherein the epigenetic modification comprises aberrant methylation.
9. (original) The method of claim 8, wherein the aberrant methylation comprises hypermethylation.
10. (original) The method of claim 6, wherein the human DNA having an epigenetic modification comprises a gene and/or a promoter region of a gene.

11. (original) The method of claim 10, wherein the gene is selected from the group consisting of *PHACTR3*, *NDRG4*, *FOXE1*, *GATA4*, *GPNMB*, *TFPI2*, *SOX17*, *SYNE1*, *LAMA*, *MMP2*, *OSMR*, *SFRP2*, and *CDO1*.
12. (original) The method of claim 6, wherein testing the nucleic acid for the presence of human DNA having an epigenetic modification comprises modifying the nucleic acid with bisulfite ions under conditions wherein unmethylated cytosine is converted to uracil.
13. (original) The method of claim 5, wherein determining expression from the human gene comprises measuring an amount of RNA expressed from the human gene.
14. (original) The method of claim 13, wherein measuring an amount of RNA expressed from the human gene comprises reverse transcriptase polymerase chain reaction (RT-PCR).
15. (original) The method of claim 4, wherein testing for an amount of a blood protein present in the second portion comprises testing for a concentration of hemoglobin in the second portion, wherein a concentration of hemoglobin is indicative of a presence of blood in the fecal sample.
16. (original) The method of claim 15, wherein testing for the concentration of hemoglobin comprises immunochemical detection of hemoglobin.
17. (original) The method of claim 15, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least 5 ng/ml.
18. (original) The method of claim 15, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least 10 ng/ml.

19. (original) The method of claim 15, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least 20 ng/ml.

20. (original) The method of claim 15, wherein the second portion of the fecal sample is considered positive for the presence of blood when the concentration of hemoglobin detected in the second portion is at least 50 ng/ml.

REMARKS

Information Disclosure Statements

Claims 1-20 are pending in the present application. Applicant notes with appreciation that the Examiner has considered the references disclosed by the Applicant in the Information Disclosure Statements filed in this matter on 03/07/2023 and 06/08/2023.

Claim Amendments

For business reasons and without acquiescing to Examiner arguments, and reserving the right to prosecute the original or similar claims in one or more future applications, Applicant herein cancels claim 3 without prejudice.

Office Action

In an Office Action mailed 07/06/2023, the Examiner provisionally rejected all claims on the grounds of non-statutory obviousness-type double patenting over claims 1-19 of co-pending Application Ser No. 18/179,961.

The Examiner additionally rejects Claims 1-20 over claims 1-20 of U.S. Patent No. 11,634,781.

Solely in the interest of expediting prosecution, Applicant herewith files terminal disclaimers over Application Ser. No. 18/179,961 and US Patent No. 11,634,781 to obviate the present rejections. Applicant notes that the filing of a terminal disclaimer to obviate a rejection based on non-statutory double patenting is not an admission of the propriety of the rejection.

CONCLUSION

It is respectfully submitted that all grounds for rejection have been addressed and Applicant's claims should be passed to allowance. Should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicant encourages the Examiner to call the undersigned at (608) 662-1277.

Dated: October 6, 2023

/Mary Ann D. Brow/

Mary Ann D. Brow
Registration No. 42,363

CASIMIR JONES, S.C.
2275 Deming Way, Suite 310
Middleton, Wisconsin 53562
608.662.1277

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**Docket Number (Optional)
EXCTD-35239.307

In re Application of: Joost Louwagie

Application No.: 18/179,945

Filed: 7 March 2023

For: FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD

The applicant, Exact Sciences Corporation, owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patent** No. 11,634,781 as the term of said **prior patent** is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 42363

/Mary Ann D. Brow/ 10/06/2023
Signature Date

Mary Ann D. Brow
Typed or printed name

Attorney 608-662-1277
Title Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0031. Public burden for this form is estimated to average 12 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. If filing this completed form by mail, send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013). <https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to: 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law; 2) a Federal, state, local, or international agency, in response to its request; 3) a contractor of the USPTO having need for the information in order to perform a contract; 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record; 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record; 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations; 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals; 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)); 9) the Office of Personnel Management (OPM) for personnel research purposes; and 9) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

Additional Uses

Additional USPTO uses of the information in this record may include disclosure to: 1) the International Bureau of the World Intellectual Property Organization, if the record is related to an international application filed under the Patent Cooperation Treaty; 2) the public i) after publication of the application pursuant to 35 U.S.C. 122(b), ii) after issuance of a patent pursuant to 35 U.S.C. 151, iii) if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections, or an issued patent, or iv) without publication of the application or patent under the specific circumstances provided for by 37 CFR 1.14(a)(1)(v)-(vii); and/or 3) the National Archives and Records Administration, for inspection of records.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING
REJECTION OVER A PENDING "REFERENCE" APPLICATION**

Docket Number (Optional)

EXCTD-35239.307

In re Application of: Joost Louwagie

Application No.: 18/179,945

Filed: 7 March 2023

For: FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD

The applicant, Exact Sciences Corporation, owner of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 18/179,961, filed, 7 March 2023, as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the applicant does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent granted on the pending **reference** application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.

I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 42363

/Mary Ann D. Brow/

Signature

10/06/2023

Date

Mary Ann D. Brow

Typed or printed name

Attorney

Title

608-662-1277

Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0031. Public burden for this form is estimated to average 12 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. If filing this completed form by mail, send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013). <https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to: 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law; 2) a Federal, state, local, or international agency, in response to its request; 3) a contractor of the USPTO having need for the information in order to perform a contract; 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record; 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record; 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations; 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals; 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)); 9) the Office of Personnel Management (OPM) for personnel research purposes; and 9) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

Additional Uses

Additional USPTO uses of the information in this record may include disclosure to: 1) the International Bureau of the World Intellectual Property Organization, if the record is related to an international application filed under the Patent Cooperation Treaty; 2) the public i) after publication of the application pursuant to 35 U.S.C. 122(b), ii) after issuance of a patent pursuant to 35 U.S.C. 151, iii) if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections, or an issued patent, or iv) without publication of the application or patent under the specific circumstances provided for by 37 CFR 1.14(a)(1)(v)-(vii); and/or 3) the National Archives and Records Administration, for inspection of records.